Top Markets
#1 Bedrock Bedrock +51.79%
#2 pippin pippin +19.58%
#3 IQ IQ +19.18%
#4 Naoris Protocol Naoris Protocol +18.03%
#5 Irys Irys +17.31%
#6 ETHGas ETHGas +16.17%
#7 Aria.AI Aria.AI +14.78%
#8 Buttcoin Buttcoin +14.36%
#9 Magma Finance Magma Finance +14.06%
#10 DUSK Network DUSK Network +11.60%
Coin of the day
Bedrock Bedrock
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rangering i aksjer #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Aksjekurs
$0.16328419
Markedsverdi
$204.14K
Endring (1 dag)
4.35%
Endring (1 år)
102.45%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategori

Healthcare
Inntekter for Fusion Antibodies plc (FAB)
Inntekter i Sep 2025 TTM: $2.15M
Ifølge de nyeste økonomiske rapportene til Fusion Antibodies plc er selskapets nåværende inntekter (TTM) $2.15M. I 2024 hadde selskapet inntekter på $1.43M en nedgang sammenlignet med inntektene i 2023, som var $3.58M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Fusion Antibodies plc fra 2013 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 2,257,473.65%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 560,997.32%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 668,407.67%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 423,215.14%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 255,843.08%
NL